Biosimilars and Generics: A New Class Needed for Hormonal and Herbal Preparations

Authors

  • Sanjay Kalra Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
  • Megha Sharma Dept. of Emergency Medicine, Government Medical College, Chandigarh, India
  • Nitin Kapoor Dept. of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia

DOI:

https://doi.org/10.59793/ijcp.v34i4.594

Keywords:

good manufacturing practice, Estrogen, herbal products, hormones, pharmacovigilance, phytopharmaceutical, thyroxine

Abstract

Strict regulations are in place for the manufacture and approval of pharmaceutical products. Specific drugs such as biological products are governed by specific rules, which take cognizance of the extra diligence required for their production. This communication describes two classes of drugs: hormones and herbal products, which should be subject to stringent regulations. It explains the rationale behind this, and calls for added vigilance in regulatory oversight.

Downloads

Published

2023-09-19

Issue

Vol. 34 No. 4 (2023)

Section

Guest Editorial

How to Cite

Biosimilars and Generics: A New Class Needed for Hormonal and Herbal Preparations. (2023). Indian Journal Of Clinical Practice, 34(4), 7-8. https://doi.org/10.59793/ijcp.v34i4.594

Similar Articles

1-10 of 52

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 > >>